The board turmoil represents a breakdown in relations between the company and its controlling shareholder. ...

PresentationGood day, and thank you for standing by. Welcome to the Novo Nordisk to convene Extraordinary General Meeting Webcast and Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Jacob Rode, Head of IR. Please go ahead.Jacob Martin RodeHead of Investor Relations Thank you, and welcome to this conference call regarding the convening of an Extraordinary General Meeting that was an ...

Core Insights - Novo Nordisk received FDA approval for Rybelsus to include cardiovascular risk reduction in adults with type II diabetes [1][6] - Rybelsus is the first oral GLP-1 therapy approved for lowering the risk of major adverse cardiovascular events in high-risk T2D patients [2][6] - The approval is based on positive results from the phase IIIb SOUL study, which showed a 14% relative risk reduction in major cardiovascular events compared to placebo [6][8] Company Developments - Rybelsus was initially approved in 2019 for improving blood sugar control in adults with T2D [3] - The label expansion in the EU also reflects MACE risk reduction for adult T2D patients [3] - The SOUL study indicated that 12% of patients on Rybelsus experienced a CV event compared to 13.8% in the placebo group, resulting in a 2% absolute risk reduction at three years [8] Clinical Data - The SOUL study demonstrated a statistically significant 14% relative risk reduction in major cardiovascular events for Rybelsus [6][8] - Safety profile in the SOUL study was consistent with previous studies, with serious adverse events slightly lower in the Rybelsus group [9] - Gastrointestinal side effects and discontinuation rates due to adverse events were higher in the Rybelsus group compared to placebo [9] Future Prospects - Novo Nordisk is seeking approval for a 25 mg oral formulation of semaglutide (Wegovy pill) for obesity and cardiovascular disease [11] - The company is also pursuing label expansion for Ozempic in treating peripheral artery disease in the U.S. and EU [11] - By broadening indications and introducing new formulations, Novo Nordisk aims to reinforce semaglutide's role in diabetes, obesity, and cardiometabolic diseases [12]

Core Insights - Novo Nordisk is experiencing significant corporate changes with the resignation of Chairman Helge Lund and six independent board members [1] Company Overview - Novo Nordisk is a leading Danish pharmaceutical company known for its successful weight loss drugs, Wegovy and Ozempic [1] Corporate Governance - The resignation of key figures in the company’s leadership raises questions about its governance and future direction [1]

Summary of Novo Nordisk Extraordinary General Meeting Conference Call Company Overview - **Company**: Novo Nordisk - **Event**: Extraordinary General Meeting scheduled for November 14, 2025 - **Focus**: Proposed future board composition Key Points and Arguments Board Composition Changes - The current board will not stand for re-election, including Chair Helge Lund and Vice Chair Henrik Poulsen [4][5] - The Novo Nordisk Foundation and the current board had differing views on the extent of board renewal, leading to the decision to convene an extraordinary general meeting [4][19] - The foundation sought a more comprehensive reconfiguration, while the board preferred a gradual addition of new competencies [4][19] New Board Members Nominated - Five new members are proposed for the board: - **Lars Rebien Sørensen** (Chair) - aims to support management for 2-3 years [7] - **Kes de Jong** (Vice Chair) - has a background in biotech [7] - **Mikael Dolsten** - former Chief Science Officer at Pfizer [8] - **Britt Meelby Jensen** - CEO of Ambu, with prior experience at Zealand Pharma and Novo Nordisk [8] - **Stefan Engels** - former Group CFO of Danske Bank [8] - Two additional candidates will be identified for the Annual General Meeting in March 2026, including **Helena Saxon**, who has extensive experience in the investment industry [9] Strategic Focus and Market Dynamics - Novo Nordisk is undergoing a transformation to adapt to a dynamic and consumer-oriented obesity market, which has seen a slowdown in growth [6] - The company aims to simplify its organization and improve decision-making speed to capitalize on growth opportunities in diabetes and obesity [6][10] - The new board composition is intended to support the management team in executing the transformation strategy [10] Competencies and Market Experience - The board recognizes the need for competencies related to the U.S. market and consumer experience, particularly in the obesity sector [14][35] - There is a focus on enhancing decision-making speed and adapting to market changes, especially in the U.S. [27][39] - The new board members are expected to bring relevant experience, although some questions were raised about the lack of global pharma commercial experience among the new nominees [43] Governance and Shareholder Engagement - The foundation aims to improve governance and engage in more preparatory dialogue with shareholders regarding board competencies and company strategy in the future [30] - The urgency of the board changes was driven by the inability to reach an agreement on the scope of changes needed [19][49] Conclusion - The extraordinary general meeting is a pivotal moment for Novo Nordisk as it seeks to align its board with the evolving market landscape and enhance its strategic direction in diabetes and obesity management [10][49]

An extraordinary meeting will take place next month to vote on new members after the company and its controlling shareholder failed to agree on the board's composition. ...

Core Insights - Novo Nordisk, the maker of Ozempic, is undergoing significant changes in its board structure to enhance governance and strategic direction [1] Group 1: Company Changes - The company is appointing new board members to bring diverse expertise and perspectives [1] - These changes are part of a broader strategy to adapt to the evolving healthcare landscape and address shareholder concerns [1] Group 2: Market Impact - The restructuring is expected to strengthen Novo Nordisk's position in the competitive pharmaceutical market, particularly in diabetes and obesity treatments [1] - Investors are closely monitoring these developments as they may influence the company's future performance and stock valuation [1]

Dave Moore, thanks so much for sitting down and chatting with us. On Friday, the FDA approved rebels for yet another indication. Rebelsis is a pill form of simaglletide.This is one of the things that everyone is watching. What does that mean for you as you get another indication for rebelsis and what does that mean for the manufacturing of those pills. >> Yeah, thanks Bertha.It's great to be with you here at health. It's a really exciting conference. Uh we were very pleased to receive the approval on Friday ...

Core Viewpoint - Novo Nordisk is experiencing a leadership shake-up as several board members will resign following disagreements with the controlling shareholder regarding the board's future composition [2][3]. Group 1: Board Composition and Changes - The board proposed a renewal that focuses on adding new competencies while maintaining continuity, but the Novo Nordisk Foundation sought a more extensive reconfiguration [2]. - Key board members, including Chair Helge Lund and Vice Chair Henrik Poulsen, will not stand for election at the upcoming Extraordinary General Meeting scheduled for November 14 [3]. Group 2: Market Reaction - Following the announcement, shares of Novo Nordisk traded 1.2% lower as of 1:41 p.m. London time [3].

Core Viewpoint - Novo Nordisk announced that its Chair Helge Lund and six other board members will resign at an extraordinary general meeting scheduled for November 14 [1] Group 1 - The resignation of the Chair and board members indicates potential changes in corporate governance [1] - The timing of the extraordinary general meeting suggests a significant shift in the company's leadership structure [1]